Generex granted another patent for RapidMist, expands protection of device

By E. Janene Geiss

Philadelphia, Jan. 5 - Generex Biotechnology Corp. announced Thursday that it has been granted another U.S. patent relating to the formulation and methodology for cleaning the company's proprietary RapidMist device.

The patent is entitled, "Cleaning Compounds for and Method of Cleaning Valves and Actuators of Metered Dose Dispensers Containing Pharmaceutical Compositions," according to a company news release.

The RapidMist device is designed to deliver pharmaceutical products, including Oral-lyn, the company's proprietary oral insulin product, into the buccal cavity in the mouth where it is absorbed into the bloodstream, the release said.

The patent covers a method of cleaning the RapidMist metered dose spray device and a cleaning composition to prevent the device from becoming clogged with medication, officials said.

The cleaning composition is non-toxic and will not harm the user of the device following cleaning, officials said.

This process makes the RapidMist device suitable for long-term, chronic use and ensures the accuracy and efficacy of the metered medication doses, officials said.

Generex is engaged in the research and development of drug delivery systems and technologies. The Toronto company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.